Last reviewed · How we verify

Sodium Chloride 0.9% infusion

Hospital Central "Dr. Ignacio Morones Prieto" · FDA-approved active Small molecule

Sodium Chloride 0.9% infusion is a Crystalloid fluid / Electrolyte replacement solution Small molecule drug developed by Hospital Central "Dr. Ignacio Morones Prieto". It is currently FDA-approved for Fluid and electrolyte replacement in dehydration, Maintenance of intravascular volume during surgery or critical illness, Vehicle for intravenous medication administration. Also known as: Placebo.

Sodium chloride 0.9% infusion replaces fluid and electrolytes to maintain osmotic balance and restore intravascular volume.

Sodium chloride 0.9% infusion replaces fluid and electrolytes to maintain osmotic balance and restore intravascular volume. Used for Fluid and electrolyte replacement in dehydration, Maintenance of intravascular volume during surgery or critical illness, Vehicle for intravenous medication administration.

At a glance

Generic nameSodium Chloride 0.9% infusion
Also known asPlacebo
SponsorHospital Central "Dr. Ignacio Morones Prieto"
Drug classCrystalloid fluid / Electrolyte replacement solution
ModalitySmall molecule
Therapeutic areaFluid and Electrolyte Management
PhaseFDA-approved

Mechanism of action

This isotonic crystalloid solution contains sodium and chloride ions in physiologic concentrations (154 mEq/L each) that match plasma osmolality (~308 mOsm/L). When administered intravenously, it expands the extracellular fluid compartment, restores circulating blood volume, and maintains electrolyte homeostasis without causing cellular water shifts.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sodium Chloride 0.9% infusion

What is Sodium Chloride 0.9% infusion?

Sodium Chloride 0.9% infusion is a Crystalloid fluid / Electrolyte replacement solution drug developed by Hospital Central "Dr. Ignacio Morones Prieto", indicated for Fluid and electrolyte replacement in dehydration, Maintenance of intravascular volume during surgery or critical illness, Vehicle for intravenous medication administration.

How does Sodium Chloride 0.9% infusion work?

Sodium chloride 0.9% infusion replaces fluid and electrolytes to maintain osmotic balance and restore intravascular volume.

What is Sodium Chloride 0.9% infusion used for?

Sodium Chloride 0.9% infusion is indicated for Fluid and electrolyte replacement in dehydration, Maintenance of intravascular volume during surgery or critical illness, Vehicle for intravenous medication administration, Treatment of hypovolemic shock.

Who makes Sodium Chloride 0.9% infusion?

Sodium Chloride 0.9% infusion is developed and marketed by Hospital Central "Dr. Ignacio Morones Prieto" (see full Hospital Central "Dr. Ignacio Morones Prieto" pipeline at /company/hospital-central-dr-ignacio-morones-prieto).

Is Sodium Chloride 0.9% infusion also known as anything else?

Sodium Chloride 0.9% infusion is also known as Placebo.

What drug class is Sodium Chloride 0.9% infusion in?

Sodium Chloride 0.9% infusion belongs to the Crystalloid fluid / Electrolyte replacement solution class. See all Crystalloid fluid / Electrolyte replacement solution drugs at /class/crystalloid-fluid-electrolyte-replacement-solution.

What development phase is Sodium Chloride 0.9% infusion in?

Sodium Chloride 0.9% infusion is FDA-approved (marketed).

What are the side effects of Sodium Chloride 0.9% infusion?

Common side effects of Sodium Chloride 0.9% infusion include Hyperchloremic acidosis, Hypernatremia, Fluid overload / pulmonary edema, Phlebitis at infusion site.

Related